CompletedPhase 3NCT01371565

Compassionate Use of CORLUX® (Mifepristone) in the Treatment of Signs and Symptoms of Endogenous Cushing's Syndrome

Studying Pituitary tumor

Last synced from ClinicalTrials.gov May 8, 2026

ℹ

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.

Report missing data

Key facts

Sponsor: Corcept Therapeutics
Principal Investigator: Coleman Gross, M.D., M.D
Corcept Therapeutics
Intervention: Mifepristone(drug)
Enrollment: 4 enrolled
Eligibility: 18 years · All sexes
Timeline: 2010 – 2012

Study locations (5)

The Center for Diabetes and Endocrine Care, Hollywood, Florida, United States
Sinai Hospital of Baltimore, Baltimore, Maryland, United States
University of Michigan Medical Center, Ann Arbor, Michigan, United States
Cleveland Clinic Foundation, Cleveland, Ohio, United States
The Ohio State University, Division of Endocrinology Diabetes and Metabolism, Columbus, Ohio, United States

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT01371565 on ClinicalTrials.gov

Other trials for Pituitary tumor

Additional recruiting or active studies for the same condition.

See all trials for Pituitary tumor →

← Back to all trials